Investigating how Myc gene expression affects protein production in cancer cells
Official title: Defining protein translation dynamics in cancers with differential Myc expression
Funded at Johns Hopkins University · NIH-11136836 · Data updated 2026-11-12
This study is looking at how a gene called Myc affects cancer cells and their ability to grow and resist treatment, with the hope that understanding this could help improve cancer care for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $54,538 |
| NIH project number | 5F30CA288019-02 |
| Project ID | NIH-11136836 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with cancers characterized by high Myc expression, such as Burkitt lymphoma.
✕Less likely to help
Patients with cancers that do not involve Myc expression or those with early-stage cancers may not benefit from this research.
What this research studies
This research focuses on understanding the role of the Myc oncogene in cancer, particularly how it influences protein synthesis and affects cancer cell behavior. By examining the dynamics of protein translation in cancers with varying levels of Myc expression, the study aims to uncover mechanisms that lead to cancer progression and treatment resistance. The approach involves analyzing stress-response pathways activated by ribosome collisions, which may contribute to the survival and growth of cancer cells. Patients may benefit from insights gained into how Myc-driven protein synthesis impacts cancer treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies targeting protein synthesis in cancers with high Myc expression.
How similar studies have gone: Previous research has shown that targeting protein synthesis pathways can be effective in treating cancers, suggesting potential success for this approach.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Schole, Kate — Johns Hopkins University
- Study coordinator: Schole, Kate
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.